Ipsos has launched three new syndicated studies monitoring the wider impact of anti-obesity medications.
According to the firm, novel anti-obesity medications (AOMs), with their efficacy in generating weight loss, are 'poised to transform the management of obesity'. These same AOMs are also showing what the firm says is 'significant promise' in the treatment of cardiometabolic and renal diseases associated with obesity. Providing clients with a view of this landscape, the new studies will run multiple times per year, with data available to multiple subscribers, and analysis and deliverables tailored to client needs.
Part of Ipsos' Global Therapy Monitor portfolio, the new 'Ipsos Global Obesity & Cardiometabolic Disease Therapy Monitor' will provide real-world treatment data on patients receiving AOMs, combined with perceptions of treating healthcare professionals (HCPs) across all relevant specialties. Subscribers will gain an ongoing understanding of current clinical practices, patient caseloads and flow, treatment dynamics, the role of concomitant conditions in treatment choice, awareness / perceptions of drugs and many other factors. The monitor is launched in the US, Germany, Japan and China, with other markets available next year, and data will be available in January 2024.
In parallel, the 'Ipsos Global Consumer Obesity Study' will monitor users' experiences of AOMs and uncover the attitudes and behaviour of the treatment-eligible and general population around AOMs and health in general. The study, which will also monitor whether these treatments are reducing consumption in food and beverage categories such as soft drinks and fast food, is available in the US and Germany, with other markets to follow in 2024.
The third study will measure the current and likely future utilisation of this new drug class (the GLP-1 RAs) - both within obesity and for other conditions such as congestive heart failure and chronic kidney disease. Ramya Logendra (pictured), Director of Ipsos' Healthcare Syndicated Services Portfolio, comments: 'With anti-obesity medications poised to impact not just healthcare systems but lifestyles and consumption habits in general, these studies can inform the strategies of multiple stakeholders beyond pharma - including healthcare bodies, the food and beverage industry, retailers, the public sector, and others'.
Web site: www.ipsos.com .
All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas unless otherwise stated.